Genentech, Inc.

F. Hoffmann-la Roche Ag

Curis, Inc.

Piramed Limited

Genetech, Inc.

Georgette M Castanedo

Daniel P Sutherlin

Adrian Folkes

Bing-Yan Zhu

Janet Gunzner

Alan G Olivero

Irina Chuckowree

Nan Chi Wan

Simon Mathieu

Shumei Wang

Sally Oxenford

Richard A Goldsmith

Tim Heffron

Kimberly Malesky

Steven T Staben

Tracy Bayliss

Zachary Kevin Sweeney

Brian Salvatore Safina

Matthew C Lucas

Bryan K Chan

Mark E Reynolds

Mark S Stanley

Scott J Savage

Liang Bao

Michael S Dina

Rebecca L Lalonde

Stephen Colin Price

Eileen Mary Seward

Vickie H Tsui

Paul Gibbons

Guosheng Wu

Michael F T Koehler

Jennafer Dotson

Pascal Pierre Alexandre Savy

Rama Kondru

Wylie Palmer

David Goldstein

Jianwen A Feng

Christian Wiesmann

Nicole Blaquiere

Stephen Joseph Shuttleworth

Janet L Gunzner-Toste

Marie-Gabrielle Braun

Joachim Rudolph

Ramsay Beveridge

Tim Hancox

Stephen Shuttleworth

Jun Liang

Po-wai Yuen

Xiaojing Wang

Jacob Bradley Schwarz

Wendy Lee

Mark A Reynolds

Richard Pastor

Po-Wai Yuen

Emily J Hanan

Jason Burch

Jason R Zbieg

Cuong Q Ly

Robin Larouche-Gauthier

Peter Andrew Smith

Malcolm Huestis

Baihua Hu

Jean-Philippe Leclerc

Keira Garland

Alexandre Lemire

Yao Wu

Lisa Marie Barton

Yuhong Fu

Leo Fu

Christian A G N Montalbetti

Scott Savage

Michael John Lambrecht

Araz Jakalian

Marie Gabrielle Braun

Fabio Broccatelli

Janet Gunzer-Toste

Man Un Ung

Arun Yadav

William Vernier

Yunxing Cheng

Christian Weismann

Mark Stanley

Michael F Koehler

Nicole Alice Blaquiere

Irina Cchuckowree

Janet Gunzer

Bing-Yang Zhu

Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.

Pyrido-pyrimidinone and pteridinone compounds and methods of use

A compound, of formula (I): suitable for treating a cancer wherein the cancer is susceptible to inhibition of Cbl-B.

Lactams as CBL-B inhibitors selective over C-CBL

Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Phenoxy-pyridyl-pyrimidine compounds and methods of use

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Cyclic peptide antibiotics

Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pharmaceutical compounds

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R, R, R, R, m and n are as described herein.

Pyridyl inhibitors of hedgehog signalling

The invention relates to compounds of Formula (0): 

Alkynyl alcohols and methods of use

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

The invention relates to novel compounds of Formula I: 

Tricyclic compounds and methods of use therefor

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use

Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

Redwood City, CA, United States of America

Georgette M Castanedo